system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Animals, Apoptosis, Bridged-Ring Compounds, Cell Line, Tumor, Cell Proliferation, Disease-Free Survival, Drug Resistance, Neoplasm, Female, Gene Expression Regulation, Neoplastic, Humans, Inhibitor of Apoptosis Proteins, Mice, Mice, Nude, Ovarian Neoplasms, RNA Interference, RNA, Messenger, RNA, Small Interfering, Survivin, Taxoids.
user
Does silencing survivin splice variant 2B lead to antitumor activity in taxane -- resistant ovarian cancer? Context: To study the role of survivin and its splice variants in taxane-resistant ovarian cancer. We assessed the mRNA levels of survivin splice variants in ovarian cancer cell lines and ovarian tumor samples. siRNAs targeting survivin were designed to silence all survivin splice variants (T-siRNA) or survivin 2B (2B-siRNA) in vitro and orthotopic murine models of ovarian cancer. The mechanism of cell death was studied in taxane-resistant ovarian cancer cells and in tumor sections obtained from different mouse tumors. Taxane-resistant ovarian cancer cells express higher survivin mRNA levels than their taxane-sensitive counterparts. Survivin 2B expression was significantly higher in taxane-resistant compared with -sensitive cells. Silencing survivin 2B induced growth inhibitory effects similar to silencing total survivin in vitro. In addition, survivin 2B-siRNA incorporated into DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine) nanoliposomes resulted in significant reduction in tumor growth (P < 0.05) in orthotopic murine models of ovarian cancer, and these effects were similar to T-siRNA-DOPC. The antitumor effects were further enhanced in combination with docetaxel chemotherapy (P < 0.01). Finally, we found a significant association between survivin 2B expression and progression-free survival in 117 epithelial ovarian cancers obtained at primary debulking surgery.
assistant
These data identify survivin 2B as an important target in ovarian cancer and provide a translational path forward for developing new therapies against this target. Final Decision: yes